Reference Effector cell  Medium for NK cell culture Target Vehicle Method/Condition Cancer type Source of scFv Backbone Promotor Leader sequence scFV Order Linker hinge spacer Trans membrane Activation signal CAR Generation Result:CAR positive (%) + detection tool Detection time point Clinial or   pre-clinical Country of First author ClinicalTrials.gov number DOI
Uherek (Blood 2002) NK-92 X-VIVO 10 medium + 5% Human AB+100U/mL IL-2 HER2  RV — Breast, Ovarian — pL-scFv(FRP5)- -SN LTR —  VH-VL — CD8a CD3ζ CD3ζ 1 100% G418 selection + MACS cMyc + enrichment, 9E10 cMyc tag  After selection Pre-clinical  Germany https://doi.org/10.1182/blood.V100.4.1265.h81602001265_1265_1273
Schirrmann (Cancer Gene Ther 2002) YTS RPMI-1640 +10% FCS CEA Plasmid DNA BioRad GenePulser II, 20μg, 10 X 106 cells, 250uL MEM medium. 250V, 975μF Colon humanized scFv pCMX- CMV h IgG1 light chain VL-VH 218 IgG1-CH2-CH3  CD3ζ CD3ζ 1 2% after transfection; >90%  250 ug/mL G418, anti-human Fab  After selection Pre-clinical  Germany https://doi.org/10.1038/sj.cgt.7700453
Daldrup-Link (Eur Radiol 2005) NK-92 X-VIVO 10 medium + 5% Human AB+100U/mL IL-2 HER2 RV and LV — Breast, Ovarian — pL-scFv(FRP5)- -SN LTR —  VH-VL — CD8a CD3ζ CD3ζ 1 100% G418 selection + MACS enrich, 9E10 cMyc tag  After selection Pre-clinical  Germany https://doi.org/10.1007/s00330-004-2526-7
Schirrmann (Leukemia Research 2005) YT cell RPMI-1640 +10% FCS CD33 Plasmid DNA BioRad GenePulser II, 20μg, 10 X 106 cells, 250uL MEM medium. 250V, 975μF.0.4cm cuvette AML humanized scFv pCMX- CMV h IgG1 light chain VL-VH 218 hIgG1-CH2-CH3  CD3ζ CD3ζ 1 5-10% after transfection; >90%  500 ug/mL G418 anti human Fab After selection Pre-clinical  Germany https://doi.org/10.1016/j.leukres.2004.07.005
Meier (Nucl Med Biol 2008) NK-92 X-VIVO 10 medium + 5% Human AB+100U/mL IL-2 HER2 RV — Breast, Ovarian — pL-scFv(FRP5)- -SN LTR — VH-VL — CD8a CD3ζ CD3ζ 1 100% G418 selection + cMyc MACS enrich, 9E10 cMyc tag  After selection Pre-clinical  Germany https://doi.org/10.1016/j.nucmedbio.2008.02.006
Muller (Cancer Immunol Immunother 2008) NK-92 X-VIVO 10 medium + 5% Human AB+100U/mL IL-2 CD20 RV 8 μg/ml polybrene Lymphoma, CLL — pLXSN-scFv-Neomycin R MMLV 5'LTR hIg heavy-chain VH-VL GS murine CD8a murine CD3ζ chain murine CD3ζ 1 >95% after 0,6mg/ml G418 R, 1 MACS plus 2X FACS enrichment, 9E10 anti cMyc tag Detection more than 7 days after RV transduction Pre-clinical  Germany https://doi.org/10.1007/s00262-007-0383-3
Tavri (Mol Imaging 2009) NK-92 X-VIVO 10 medium + 5% Human AB+100U/mL IL-2 EpCAM RV — Prostate — pL-scFv(MOC31)- -SN LTR — VH-VL — CD8a CD3ζ CD3ζ 1 100% G418 selection, 9E10 anti cMyc tag After selection Pre-clinical  USA https://doi.org/10.2310/7290.2009.00002
  Boissel (Leukemia Res 2009) NK-92 MyeloCult medium + 500U/mL IL-2 CD19 mRNA , plasmid DNA BioRad GenePulser II, 5/10μg, 2 X 106 cells, 250uL MEM medium. 300 mV, 150μF, 200W. CLL — pXT-GFP / pcDNA 3,1 — —  VL-VH — CD8  CD3ζ CD3ζ 1 mRNA: >85% viability , 24 hours 47.2 ± 8% CAR+ (CAR mRNA expression window 0~48 hrs), GFP
plasmid: >35% Viability, 24 Hours 0% CAR+ GFP		 24h, 48h for CAR+ Pre-clinical  USA https://doi.org/10.1016/j.leukres.2008.11.024
Meier (Magn Reson Med 2011) NK-92 X-VIVO 10 medium + 5% Human AB+100U/mL IL-2 EpCAM RV — Prostate — pL-scFv(MOC31)- -SN LTR —  VH-VL — CD8a CD3ζ CD3ζ 1 100% G418 selection + MACS enrich, 9E10 anti cMyc tag After selection Pre-clinical  USA https://doi.org/10.1002/mrm.22652
Sahm (Cancer Immunol Immunother 2012) NK-92, NKL  X-Vivo 10 Medium + 5% Human AB +100U/mL IL-2 EpCAM LV (VSV-G, 2nd gen.) 8 μg/mL polybrene Breast  codon-optimized pHR’SIN-cPPT-SIEW IRES-EGFP SFFV hIg heavy-chain — (G4S)x3 CD8a CD28 CD28-CD3ζ 2 100% After FACS sorting cMyc+ EGFP+ 14 days no IL-2+ FACS Pre-clinical  Germany https://doi.org/10.1007/s00262-012-1212-x
  Boissel (Leukemia Lymphoma 2012) NK-92  MyeloCult medium + 500U/mL IL-2 CD19, CD20 mRNA, LV mRNA: BioRad GenePulser II, 10μg, 2 X 106 cells, 250uL MEM medium. 300 mV, 150μF, 200W
LV: 8 μg/mL polybrene or 15 μg/mL protamine sulfate		 CLL murine mAb scFv mRNA: pXT7
LV: pCL20c-IRES-GFP 		 MSCV hIg heavy-chain VH-VL GS CD8a  CD3ζ  CD3ζ 1 plasmid: 55.8% ± 5.8%  GFP
LV: 25.6%±4.2 GFP		 24 h after electroporation or 48-72 h after transduction Pre-clinical  USA https://doi.org/10.3109/10428194.2011.634048
Esser (J Cell Mol Med 2012) NK-92 X-VIVO 10 medium + 5% Human AB+100U/mL IL-2 GD2 RV 8 μg/mL polybrene Neuroblastoma  — pL-scFv(FRP5)- -SN LTR hIg heavy-chain VL-VH (G4S)x4 CD8a CD3ζ CD3ζ 1 100% G418 selection + cMyc MACS enrichment After selection Pre-clinical  Germany https://doi.org/10.1111/j.1582-4934.2011.01343.x
Tassev (Cancer Gene Ther 2012) NK-92-MI alpha-MEM EBNA RV (VSV-G, ampho) LentiX concentrator B-ALL — pFUSE—hIgG1-Fc1  MSCV CD8a — — — CD8a CD3ζ 1 >20 % GFP +, after FACS sorting > 90%   72 hrs and FACS Pre-clinical  USA https://doi.org/10.1038/cgt.2011.66
Alkins (Cancer Res 2013) NK-92 X-VIVO 10 medium + 5% Human AB+100U/mL IL-2 HER2 RV — Breast, Brain — pL-scFv(FRP5)- -SN LTR — VH-VL — CD8a CD3ζ CD3ζ 1 100% G418 selection + cMyc MACS enrichment After selection Pre-clinical  Germany https://doi.org/10.1158/0008-5472.CAN-12-2609
Boissel (OncoImmunol 2014) NK-92 MyeloCult medium + 500U/mL IL-2 CD19, CD20 LV 15 µg/mL protamine sulfate CLL murine mAb scFv  pCL20c-IRES-GFP — — VL-VH — CD8  CD3ζ CD3ζ 1 >95% by FACS sorting on GFP or mCherry or anti-scFv — Pre-clinical  USA https://doi.org/10.4161/onci.26527
Jiang (Mol Oncol 2014) NK-92-MI alpha-MEM CD138 LV (VSV-G, 3rd gen.) 8 μg/ml polybrene MOI 50-100, 5μg/mL puromycin selection for 2-3 week Multiple Myeoloma — pLenO-GTP CMV hIg heavy-chain VH-VL (G4S)x3 CD8a CD3ζ CD3ζ 1 >95% goat anti-mouse IgG (Fab specific) 2-3 Weeks after transduction Pre-clinical  China https://doi.org/10.1016/j.molonc.2013.12.001
Chu (Leukemia 2014) NK-92 RPMI-1640 +20% FCS+ 150u/mL IL-2 CS1 LV (VSV-G, 2nd gen.) 8 μg/mL polybrene Multiple Myeloma  — pCDH-CMV-MCS-EF1-copGFP CMV — VH-VL — — CD28 CD28-CD3ζ 2 100% After FACS sorting GFP After sorting Pre-clinical  USA https://doi.org/10.1038/leu.2013.279
Seidel (Cancer Immunol Immunother 2015) NK-92 X-VIVO 10 medium + 5% Human AB+100U/mL IL-2 GD2 RV 8 μg/mL polybrene Neuroblastoma  — pL-scFv(FRP5)- -SN LTR hIg heavy-chain VL-VH (G4S)x4 CD8a CD3ζ CD3ζ 1 100% G418 selection + cMyc+ MACS enrichment After selection Pre-clinical  Germany https://doi.org/10.1007/s00262-015-1669-5
Schönfeld (Mol Ther 2015) NK-92 X-VIVO 10 medium + 5% Human AB+100U/mL IL-2 HER2 LV (VSV-G, 2nd gen.) 8 μg/mL polybrene Breast  codon-optimized pHR’SIN-cPPT-SIEW IRES-EGFP SFFV hIg heavy-chain VH-VL (G4S)x3 modified CD8a CD28/CD3ζ CD28-CD3ζ/ CD137-CD3ζ/ CD3ζ 1 and 2 100% After FACS sorting cMyc+ by 9E10 tag After sorting Pre-clinical  Germany https://doi.org/10.1038/mt.2014.219
Han (Sci Reports 2015) NK-92, NKL RPMI-1640 +20% FCS+ 150u/mL IL-2 EGFR LV (VSV-G, 2nd gen.) 8 μg/mL polybrene Glioblastomas — pCDH-CMV-MCS-EF1-copGFP CMV — VH-VL — — CD28 CD28-CD3ζ 2 100% After FACS sorting GFP  After sorting Pre-clinical  USA https://doi.org/10.1038/srep11483
Topfer (J Immunol 2015) YTS, primary RPMI-1640 +10% FCS + IL-2 PSCA LV (VSV-G, 2nd gen.) 8 μg/mL polybrene Bladder — pHATtrick-T2A-EGFP SFFV Igkappa light chain — (G2S1)x2 DAP12 DAP12 DAP12 1 cMyc+ EGFP+ > 95% after Zeo seletion in YTS cell line, primary NK cells 48% (±16%)  After selection Pre-clinical  Germany https://doi.org/10.4049/jimmunol.1400330
Clémenceau (J Immunol Res 2015) NK-92 RPMI 1640 + 10% FCS+ 100U/mL IL-2 Her2 RV — Breast — pMX/CAR LTR — VL-VH — IgG2 CH2-CH3  FceRI𝛾 FceRI𝛾 1 36% anti IgG2b  4 days after transduction Pre-clinical  France https://doi.org/10.1155/2015/482089
Liu (Oncol Reports 2015) NK-92 alpha-MEM HER2 Plasmid DNA Amaxa Nucleofector system (program A-024) Breast — pcDNA3.1 CMV — VH-VL — CD8a CD28 CD28-CD3ζ 2 18.89% cMyc+, RT-PCR argose gel — Pre-clinical  China https://doi.org/10.3892/or.2014.3548
Zhao (Leukemia 2015) NK-92-MI alpha-MEM WT-1  RV plated coated 100μg/mL fibronectin or 50 μg/mL Retronectin. 4μg/mL polybrene MOI 4-6 ALL PCR from human cDNA library  pMSCV-IRES-GFP MSCV LTR CD8a — — — CD8a CD137-CD3ζ 2 20%-40% WT1 MHC/peptide tetramer — Pre-clinical  USA https://doi.org/10.1038/leu.2015.125
Muller (J Immunother 2015) YTS RPMI-1640 +10% FCS EGFRvIII LV (VSV-G, 2nd gen.) 8 μg/mL polybrene Glioblastoma — pHATtrick-T2A-EGFP SFFV Igkappa light chain — (G2S1)x2 DAP12 DAP12 DAP12 1 >95%  GFP, after Puromycin After selection Pre-clinical  Germany https://doi.org/10.1097/cji.0000000000000082
Alkins (Neuro-Oncol 2016) NK-92 X-VIVO 10 medium + 5% Human AB+100U/mL IL-2 HER2 RV — Breast, Brain — pL-scFv(FRP5)- -SN LTR — VH-VL — CD8a CD3ζ CD3ζ 1 100% G418 selection + MACS enrichment After selection Pre-clinical  Germany https://doi.org/10.1093/neuonc/nov318
Genßler et al. (OncoImmunol 2016) NK-92 X-VIVO 10 medium + 5% Human AB+100U/mL IL-2 EGFRvIII LV (VSV-G, 2nd gen.) 8 μg/mL polybrene Glioblastoma  codon-optimized pHR’SIN-cPPT-SIEW IRES-EGFP SFFV hIg heavy-chain — (G4S3)x3 modified CD8a CD28 CD28-CD3ζ 2 100% After FACS sorting cMyc by 9E10 tag After sorting Pre-clinical  Germany https://doi.org/10.1080/2162402X.2015.1119354
Zhang (J Natl Cancer Inst 2016) NK-92 X-VIVO 10 medium + 5% Human AB+100U/mL IL-2 HER2 LV (VSV-G, 2nd gen.) — Glioblastoma — pHR’SIN-cPPT-SIEW IRES-EGFP SFFV —  VH-VL — CD8a CD28-CD3ζ CD28-CD3ζ 2 100% G418 selection + MACS enrich cMyc+ by 9E10 tag After selection Pre-clinical  Germany https://doi.org/10.1093/jnci/djv375
Romanski (J Cell Mol Med 2016) NK-92 X-VIVO 10 medium + 5% Human AB+100U/mL IL-2 CD19 RV 8 μg/mL polybrene B-ALL — pL-scFv(FMC63)- -SN LTR hIg heavy-chain VL-VH (G4S)x4 CD8a CD3ζ CD3ζ 1 100% G418 selection + 4 X MACS enrichment on cMyc by 9E10 tag After selection Pre-clinical  Germany https://doi.org/10.1111/jcmm.12810
Topfer (J Immunother 2016) YTS cell RPMI-1640 + 10% FCS + IL-2 EGFRvIII LV (VSV-G, 2nd gen.) 8 μg/mL polybrene Glioblastoma — pHATtrick-T2A-EGFP SFFV Igkappa light chain — (G4S1x)3 DAP12 DAP12 DAP12 1 cMyc+ EGFP+ > 95% after puro seletion in YTS cell line After selection Pre-clinical  Germany —
Chen (Oncotarget 2016) NK-92, PB-NK RPMI-1640 + 20% FCS + 200U/mL IL-2 EGFR LV (VSV-G, 2nd gen.) 8 μg/mL polybrene Breast, Brain — pCDH-CMV-MCS-EF1-copGFP CMV — VH-VL — — CD28 CD28-CD3ζ 2 >39,2% After FACS sorting GFP After sorting Pre-clinical  USA https://doi.org/10.18632/oncotarget.8526
Siegler (Mol Ther 2017) NK-92 alpha-MEM CD19, HER2 RV and LV MOI 40 Breast — RV:pMP71 LV: pCCL and pCCW — — — — CD8a CD8a CD28-CD137-CD3ζ /CD28-CD3ζ 2 and 3 CD19 CAR biotinylated Protein L, Her2 CAR detect with rhHer2-Fc chimera antigen — Pre-clinical  USA https://doi.org/10.1016/j.ymthe.2017.08.010
Oelsner (Cytotherapy 2017) NK-92 X-Vivo 10 Medium + 5% Human AB + 100U/mL IL-2 CD19 LV (VSV-G, 2nd gen.) 8 μg/mL polybrene pre-B ALL  codon-optimized pHR’SIN-cPPT-SIEW IRES-EGFP SFFV hIg heavy-chain — (G4S)x3 modified CD8a CD28 CD28-CD3ζ/ CD137-CD3ζ/ CD3ζ 1 and 2 100% After FACS sorting cMyc+ EGFP+  WB — Pre-clinical  Germany https://doi.org/10.1016/j.jcyt.2016.10.009
Chen (Oncotarget 2017) NK-92 alpha-MEM CD3 LV (VSV-G, 2nd gen.) 15 μg/mL RetroNectin pre-coated T-cell leukemia  — pRSC.SFFV SFFV — — — CD8a CD8a CD137-CD28-CD3ζ 3 32% Fab positive after FACS sorting — Pre-clinical  USA https://doi.org/10.18632/oncotarget.11019
Chen (Leukemia 2017) NK-92 alpha-MEM CD5 LV (VSV-G, 2nd gen.) 15 μg/mL RetroNectin pre-coated T-cell leukemia  — pRSC.SFFV SFFV — — — CD8a CD8a CD137-CD28-CD3ζ 3 26% Fab Positive after FACS sorting — Pre-clinical  USA https://doi.org/10.1038/leu.2017.8
Li (Cell Stem Cell 2018) NK-92, iPSC 56.6 % DMEM-high glucose, 28.3 % HAM-S/F12 + 15 % heat-inactivated human AB mesothelin piggyBac transposon electroporation Lonza 4D-nucleofector device Ovarium — pKT2-mCAG-IRES-GFP mCAG CD8a — — CD8a NKG2D/CD28/CD16/NKp44/NKp46 2B4-CD3ζ/ CD28-CD137-CD3ζ/ DAP10-CD3ζ/ CD137-CD3ζ/ 2B4-DAP12-CD3ζ/ 2B4-DAP10-CD3ζ/ CD137-2B4-CD3ζ/ CD3ζ 1, 2 and 3 100% GFP after FACS sorting — Pre-clinical  USA https://doi.org/10.1016/j.stem.2018.06.002
Zhao (Eur J Inflamm 2018) NK-92-MI alpha-MEM CD19, CD138 LV — Multiple Myeloma — pCDH-CMV-MCS-EF1-Puro CMV Colony stimulating factor 2 receptor alpha — — Fc — CD28-CD3ζ 2 >99% FACS GFP anti Fc part After FACS  Pre-clinical  China https://doi.org/10.1177/2058739218788968
Murakami (Anticancer Res 2018) KHYG-1 RPMI 1640 + 150U/ IL-2 EGFRvIII LV  8 μg/mL polybrene Glioblastoma mouse antibody — EF1α — — — — CD28 CD137-CD3ζ 2 11% after transduction, 81% 1st MACS, >89.2% 2nd MACS  based on goat anti mouse IgG After sorting Pre-clinical  Japan https://doi.org/10.21873/anticanres.12824
Zhang (J Immunol Res 2018) NK-92 alpha-MEM EpCAM LV (2nd gen.) Retronectin MOI=5 Colon mouse antibody  pRRL-GFP EF1α — — — CD8a CD8a CD137-CD3ζ 2 79,2% GFP+, WB After sorting Pre-clinical  China https://doi.org/10.1155/2018/4263520
Yu (Mol Therapy 2018) NK-92 alpha-MEM GPC3 LV  8 mg/mL polybrene+6 mM BX795 Hepatocellular Carcinoma humanized scFv pRRLSIN-EGFP EF1α CD8a — — CD8a CD28 CD28-CD3ζ 2 >98% anti Human Fab FACS, WB After sorting Pre-clinical  China https://doi.org/10.1016/j.ymthe.2017.12.012
Nowakowska (Cancer Immunol Immunother 2018) NK-92 X-VIVO 10 medium + 5% Human AB+100U/mL IL-2 HER2 LV (VSV-G, 2nd gen.) 8 μg/mL polybrene Breast  codon-optimized pHR’SIN-cPPT-SIEW IRES-EGFP SFFV hIg heavy-chain  VH-VL (G4S)x3 modified CD8a CD28/CD3ζ CD28-CD3ζ/ CD137-CD3ζ/ CD3ζ 1 and 2 100% After FACS sorting cMyc+, 9E10 tag After sorting Pre-clinical  Germany https://doi.org/10.1007/s00262-017-2055-2
Tang (Am J Cancer Res 2018) NK-92 MI — CD33 LV (3rd gen.) — AML — — — — — — FC CD28 CD28-CD137-CD3ζ 1 and 2 >90% on Fc percentage After sorting Clinical China NCT02944162 https://pubmed.ncbi.nlm.nih.gov/30034945/
Schnalzger (EMBO J 2019) NK-92 X-VIVO 10 medium + 5% Human AB + 100U/mL IL-2 HER2 LV (VSV-G, 2nd gen.) 8 μg/mL polybrene Breast  codon-optimized pHR’SIN-cPPT-SIEW IRES-EGFP SFFV hIg heavy-chain VH-VL (G4S)x3 modified CD8a CD28 CD28-CD3ζ 2 100% After FACS sorting cMyc+ by 9E10 tag After sorting Pre-clinical  Germany https://doi.org/10.15252/embj.2018100928
Ao (J Immunother 2019) NK-92 RPMI 1640 + 10% FCS + 150 U/mL IL-2 AlphaFR LV  — Ovarium — pLenti-EF1a- EF1α CD8a — — CD8a CD28 CD3ζ/CD28-CD3ζ/ CD28-CD137-CD3ζ 1, 2 and 3 After 5ug/mL puromycin seletion, anti Fc staining mRNA vs GADPH After selection Pre-clinical  China https://doi.org/10.1097/CJI.0000000000000286
Kloess (Human Gene Therapy 2019) NK-92, PB  X-VIVO 10, CellGro, TexMACS, and NK MACS ) NK MACS + 5% human AB + 2% Supplement CD123 RV 4 μg/mL protamine sulfate + Retronectin coated, MOI 1- 3  AML scFv condon optimized  pMPSV-IRES-GFP MPSV GMCSF R alpha chain — — — CD28 CD28-CD137-CD3ζ 3 before sorting 40%; After GFP sorting His+GFP+ 78% 7 days after transduction Pre-clinical  Germany https://doi.org/10.1159/000495771
Kim (Biomaterials 2019) NK-92-MI MEM EGFR Nanoparticle-plasmid DNA 16 μg/mL nanoparticle and 2μg/mL DNA plasmids Breast — pcDNA3.1 CMV CD8a VH-VL (G4S)x3 CD8 CD28 CD28-CD3ζ 2 Fab+ 30%~60% 12 h after cell injection Pre-clinical  Korea https://doi.org/10.1016/j.biomaterials.2019.119418
Xu (J Hematol Oncol 2019) NK-92 alpha-MEM CD5 LV (VSV-G, 3rd gen.) 8 μg/ml polybrene T-cell leukemia  — pCDH-EF1a EF1a CD8a — — CD8a CD8a 2B4-CD3ζ/ CD137-CD3ζ 2 >90% GFP+ Fab+ after FACS sorting — Pre-clinical  China https://doi.org/10.1186/s13045-019-0732-7
Batchu (Surgery 2019) NK-92-MI alpha-MEM mesothelin Transposon+minicircle DNA Nucleofector Kit and 4DNucleofector
electroporation unit, Lonza		 Pancreas — pDonR-SB  EF1a CD8a VH-VL — IgG4 CD28 CD28-CD137-CD3ζ 3 > 80% protein-L FITC+  Day8 after electroporation Pre-clinical  USA https://doi.org/10.1016/j.surg.2019.05.047
Kulemzin (BMC Med Genom 2019) NK-92, YTS IMDM + 10% FCS + 200ug/mL IL-2 PMSA LV (VSV-G, 2nd gen.) 8 μg/mL polybrene Prostate — pCDH-CMV-MCS-EF1-copGFP hPGK, 4xNFAT, 2xNFkB, 5xNFkB, 10xNFkB, 30xNFkB, CD69 promoter murine Igκ-chain — — IgG1-CH2-CH3  CD28 CD28-CD3ζ 2 100% cMyc+ by 9E10 tag, GFP  After sorting Pre-clinical  Russia https://doi.org/10.1186/s12920-019-0489-4
You (Am J Cancer Res. 2019) NK-92-MI alpha-MEM CD7 Transposon Amaxa Nucleofector T-ALL  codon-optimized pHULK PiggyBac  — — — — FC CD28 CD28-4-1BB-CD3ζ 3 anti-human IgG Fc FACS sotting After sorting Pre-clinical  China https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356925/
Oelsner (Int J Cancer 2019) NK-92 X-Vivo 10 Medium + 5% AB serum + 100U/mL IL-2 FLT3 LV (VSV-G, 2nd gen.) 8 μg/mL polybrene AML  codon-optimized pHR’SIN-cPPT-SIEW IRES-EGFP SFFV hIg heavy-chain — (G4S)x3 modified CD8a CD28 CD28-CD3ζ 2 100% After FACS sorting cMyc+ EGFP+  WB After sorting Pre-clinical  Germany https://doi.org/10.1002/ijc.32269
Parlar (Eur J Immunol 2019) NK-92, YTS NK-92:SCGM + 20% FCS + 1000U/IL-2; YTS: RPMI1640 + 20% FCS CD3 δγεδ, TCR LV 8 μg/mL protamine sulfate + 3μM BX795 Melanoma —   LeGO-iT2puro SFFV — — — — TCR ab CD3ζ 1 >80% CD3 TCR ab FACS sorting  After sorting Pre-clinical  Turkey https://doi.org/10.1002/eji.201948140
Mensali (EBioMed 2019) NK-92 X-Vivo 10 Medium+ 5% AB serum +500U/mL IL-2 CD3 δγεδ, TCR RV 50 μg/mL retronectin Colon —  pMP71 — — — — — TCR ab CD3ζ 1 >98% CD3+ FACS sorting  After sorting Pre-clinical  Norway https://doi.org/10.1016/j.ebiom.2019.01.031
Ravi (Leukemia 2020) NK-92 X-Vivo 10 Medium+ 5% AB serum +50ng/mL IL-2 or Myelocult medium  CD19 LV  —  Lymphoma —  pCL20c-IRES-GFP — — — — CD8  CD3ζ CD3ζ 1 >95% by FACS sorting on GFP or mCherry or anti-scFv — Pre-clinical  USA https://doi.org/10.1038/s41375-019-0663-x
Hu, (Sci Report 2020) NK-92-MI alpha-MEM Tissue factor LV MOI 12~150 Breast — pCDH-MSCV-MCS-EF1a-GFP-Puro MSCV — — — IgG1 hinge/ without CD28 CD137-CD3ζ 2 100% after 2,5ug/mL puromycin GFP+, RT-PCR and ELISA After selection Pre-clinical  USA https://doi.org/10.1038/s41598-020-59736-3
Huang (Cancer Manag Res 2020) NK-92 alpha-MEM GPC3 LV — Liver — pCDH-EF1α-MCS EF1a — — — CD8 CD3ζ/ CD28/ 2B4/ DNAM1 CD3ζ/ CD28-CD3ζ/ 2B4-CD3ζ/ DNAM1-CD3ζ/ DNAM1-2B4-CD3ζ 1, 2 and 3 cell slides staining on the 293T cell surface, FACS on GPC3 antigen  >40% 72 hours after transduction Pre-clinical  China https://doi.org/10.2147/cmar.s253565
Mitwasi (Sci Report 2020) NK-92-MI X-Vivo 10 Medium + 5% AB serum + 500ng/mL IL-2, Myelocult medium  GD2 LV polybrene and BX795 Neuroblastoma  —  p6NST50-EGFP — — VL-VH (G4S1)x3 IgG4 CH2Ch3 CD28 CD28-CD3ζ 2 >70% anti-mouse secondary Ab After sorting Pre-clinical  Germany https://doi.org/10.1038/s41598-020-59082-4
Hambach (Cells 2020) NK-92 alpha-MEM CD38 RV (galv) 8 μg/mL polybrene Multiple Myeloma — pRSF91.Nb-CAR.iB.pre — hIg heavy-chain VH only — hIgG4 CD28 CD28-CD137-CD3ζ 3 Iinitial transduction efficiency <30%; cell sorting > 95% of cells. CD38 antigen After sorting Pre-clinical  Germany https://doi.org/10.3390/cells9020321
Cao (Biochem Biophys Res Commun 2020) NK-92 alpha-MEM Mesothelin, CD19 LV (2nd gen.) — Ovarium —  pWPXLd-2A-eGFP  EF1a CD8a — — CD8 CD28 CD28-CD137-CD3ζ 3 >99 GFP+ and RT PCR After sorting Pre-clinical  China https://doi.org/10.1016/j.bbrc.2020.01.053
Li (J Cancer Res Ther 2020) NK-92 — Robo LV — Pancreas — — — — — — CD8 CD8a CD137-CD3ζ 2 >96 CAR+ After sorting Clinical China NCT03941457 https://doi.org/10.4103/jcrt.JCRT_190_20
Montagner (Cells 2020) NK-92 alpha-MEM PMSA LV 40μg/mL protamine sulfate  Prostate — pCCL-hPGK- hPGK — — — CD28 CD28 CD28-CD3ζ 2 >99 GFP+  After sorting Pre-clinical  Italy https://doi.org/10.3390/cells9061382
Nakazawa (Anticancer Res 2020) KHYG-1 RPMI 1640 + 150U/ IL-2 EGFRvIII LV  8 μg/mL polybrene Glioblastoma mouse antibody — EF1α — — — — CD28 CD137-CD3ζ 2 11% after transdcution, 81% 1st MACS, >89.2% 2nd MACS  based on goat anti mouse IgG After sorting Pre-clinical  Japan https://doi.org/10.21873/anticanres.14304
Robbins (eLife 2020) NK-92 X-Vivo 10 Medium + 5% human AB PDL1 — — Head, neck cancer — — — — — — CD8 CD28 FceR1gamma 1 100% — Pre-clinical  USA https://doi.org/10.7554/eLife.54854
Lee (J Control Release 2020) NK-92 alpha-MEM Fra, TRAIL LV Lenti-X and  8 μg/
ml polybrene 		 Pancreas — — — — — — — — CD27-CD3ζ 2 FACS sorting — Pre-clinical  South Korea https://doi.org/10.1016/j.jconrel.2020.07.016
Liu (Cytotherapy 2020) NK-92 MI alpha-MEM CD19 LV (3rd gen.) 8 μg/ml polybrene B-ALL mouse antibody pCDH-EF1a EF1a CD8a — — CD8a CD8a CD137-CD3ζ 2 >90% GFP+ Fab+ after FACS sorting — Pre-clinical  China https://doi.org/10.1016/j.jcyt.2020.06.003
Yang (Front Pharmacol 2020) NK-92 MI alpha-MEM B7H3 LV (2nd gen.) 8 μg/ml polybrene Lung human IgG pLVX-EF1-IRES-ZsGreen EF1 hIg heavy-chain — — — CD8 CD137-CD3ζ 2 ZsGreen Positive Positive After sorting Pre-clinical  China https://doi.org/10.3389/fphar.2020.01089
Jamali (Front immunol 2020) NK-92, NKL, PB X-Vivo 10 CD19 LV (3rd gen.) 8 μg/ml polybrene B-ALL humanized scFv SINpWPT-EF1a EF1a — VL-VH — CD8a 4-1BB CD137-CD3ζ 2 >90% sorting out on CD19+ 72 hours after transduction Pre-clinical  Iran https://doi.org/10.3389/fimmu.2020.02028
Ahn (Biomaterials 2020) NK-92 alpha-MEM EGFR — — Breast — — — — — — — — CD28-DAP10-CD3ζ 3 — — Pre-clinical  South Korea   https://doi.org/10.1016/j.biomaterials.2020.119960
Fabian (J Immunother Cancer 2020) NK-92 X-Vivo 10 PD-L1 — — Breast — — — — — — — — FcεRIγ — — — Pre-clinical  USA   https://doi.org/10.1136/jitc-2019-000450
Gurney (Haematologica 2020) KHYG-1, PB-NK RPMI1640 CD38 RV — AML — — — — — — — — CD28-CD3ζ 2 — — Pre-clinical  Ireland   https://doi.org/10.3324/haematol.2020.271908
Tseng (Nat Commun 2020) NK-92MI, PB-NK alpha-MEM CD147, GPC3 RV, LV (2nd gen) 0.5 µg/ml RetroNectin Liver mouse antibody SFG-RV/ pHR-LV SFG-RV/PGK-LV — — — hIgG1 CD28 CD28-CD137-CD3ζ 3 CAR-NK92MI sorting out > 95% Fab positive, PB-NK 80% Fab After sorting Pre-clinical  USA   https://doi.org/10.1038/s41467-020-18444-2
Eitler (J Immunother Cancer 2021) NK-92 X-VIVO 10 medium + 5% Human AB serum + 100U/mL IL-2 HER2 LV (VSV-G, 2nd gen) 8 μg/mL polybrene Breast  codon-optimized pHR’SIN-cPPT-SIEW IRES-EGFP SFFV hIg heavy-chain VH-VL (G4S)x3 modified CD8a CD28/CD3ζ CD28-CD3ζ 2 100% After FACS sorting cMyc+ by 9E10 tag After sorting Pre-clinical  Germany   https://doi.org/10.1136/jitc-2020-001334
Kang (Int J Mol Sci 2021) NK-92MI, KHYG-1 RPMI1640 CD19 LV (3rd gen) Lenti-X, Polybrene B-ALL — pLVX CMV/EF1a/hPGK — VL-VH — CD28 CD28 CD28-CD3ζ 2 WB assay — Pre-clinical  South Korea   https://doi.org/10.3390/ijms21239163
Abbreviations: — denotes details that were not mentioned in the original publiction. PB-NK: peripheral blood NK cells. CB-NK: cord-blood NK cells. iPSC: induced pluripotent stem cell. scFv: single chain variable fragmenet. LV: lentivirus. RV: retrovirus. G4S: 4-glycine serine (linker).